PURPOSE 3/ HPTN 102
Status:Planned
Phase:Open Label
Principal Investigator(s):
Objective:A Randomized, Open-Label Study of Acceptability and Use of Lenacapavir vs TDF/FTC Among US WomenStudy is planned as of Dec 2021 shown here; this upcoming study was also mentioned at HPTN 2022Last updated June 10, 2022
Prevention Option(s):PrEP
Study Design:Open label, Randomized
Arms and Assigned Interventions
Description
Mode of Delivery
ARMsExperimental
Description
Mode of Delivery
ARMsActive Comparator
Start Date
End Date
none
none
Enrollment:0
Age range:
↔
any
Population:Cisgender Women